Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach

Giovanni Palladini, Paolo Milani, Andrea Foli, Laura Obici, Francesca Lavatelli, Mario Nuvolone, Riccardo Caccialanza, Stefano Perlini, and Giampaolo Merlini

Amyloidosis Research and Treatment Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy and Department of Molecular Medicine, University of Pavia; Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo and University of Pavia; Nutrition and Dietetics Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

©2014 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2013.095463
Manuscript received on July 22, 2013. Manuscript accepted on November 4, 2013.
Correspondence: gmerlini@unipv.it
Supplemental methods

Eligibility for transplantation
Eligibility criteria for ASCT are detailed in the online Supplement were age <65 years, performance status (Eastern Cooperative Oncology Group) <3, normal cTnI concentration, ejection fraction >45%, estimated glomerular filtration rate (eGFR) >50 mL/min per 1.73 m², systolic blood pressure >90 mmHg (standing), and lung CO diffusion capacity >50%.

Assessment of toxicity
Toxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Statistical methods
Multiple logistic regression was used to compare response rates in various subgroups while adjusting for potential confounders. Receiver Operator Characteristic (ROC) curve analysis was used to identify the cutoffs of NT-proBNP, cardiac troponin I (cTnI) and dFLC best predicting death at 12 months. Cox multivariable models were fitted including predictors showing a $P<0.1$ at univariable analysis. A 3-month landmark analysis of response was performed.